MET and lung adenocarcinoma: The reciprocal crosstalk between EGFR and MET in lung adenocarcinoma suggests that simultaneous inhibition through the combined use of EGFR-TKI and MET-TKI would benefit and potentially improve the survival outcomes of patients with concurrent EGFR and MET aberrations (17, 18).